Abstract
Introduction Post-marketing safety surveillance is indispensable for ensuring safety and public trust in vaccines, particularly in African settings where evidence of COVID–19 vaccine safety is less documented. We aimed to identify the types of adverse events following immunization (AEFIs), the overall incidence, and factors associated with AEFIs during mass vaccination campaigns in The Democratic Republic of Congo (DRC).
Methods From December 1 to 29, 2023, a prospective safety surveillance study was conducted on 4,766 individuals in Kinshasa Province in DRC. They were surveyed through phone calls from day 1 to 28 following the administration of the COVID-19 vaccine. We calculated AEFI incidence rates by type of vaccine, sex, and age group. We identified factors associated with AEFIs using multivariable logistic regression models, which were expressed by adjusted odds ratio (aOR) and its 95% confidence interval (CI).
Results A total of 4766 participants were included in the study. The median age of the participants was 36 years, with an interquartile range of 27 to 48 years and 2503 (53%) were females. Most of the participants (94.6%) received the Johnson & Johnson (J&J) vaccine, while 256 (5.4%) received the Pfizer vaccine. Nearly a quarter of participants (23.75%, 95% CI: 22.54%-24.99%) reported AEFIs. The most common AEFIs reported were fever (9.61%, 95%CI: 8.88%-10.48%), injection site pain (9.00%, 95%CI: 8.20%-9.85%), headache (4.11%, 95%CI: 3.57%-4.72%), stiffness (1.51%, 95%CI: 1.18%-1.89 %) and myalgia (1.15%, 95%CI: 0.87%-1.49%). The incidence of AEFIs was higher for the Pfizer vaccine at 34.48% (95% CI: 28.57%-40.54%) compared to 23.15% (95% CI: 21.92%-24.41%) for the J&J vaccine. Participants aged 36 years and above were associated with increased odds of reporting any adverse event (aOR=1.17, 95%CI: 1.02-1.33), injection site pain (aOR=1.36, 95% CI: 1.11-1.66), and two or more signs (aOR=1.46, 95%CI: 1.10-1.94), compared to those below 36 years of age.
Conclusions AEFI reported by about a quarter of participants and its association with vaccine type and older age underscores the need for systematic vaccine safety monitoring in the population. This is critical for developing future vaccination strategies tailored to individuals more susceptible to AEFIs.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was provided by the Ethics Committee of the School of Public Health at University of Kinshasa in Democratic Republic of Congo
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Footnotes
Contributorship: “KK and AD are Joint First Authors”
Data Availability
The quantitative data analyzed is not publicly available, being the property of the DRC Ministry of Health however, access may be granted with reasonable request and approval by the Ministry
